NCT07212426View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

May 6, 2026

Study Completion Date

March 31, 2028

Conditions
PNH - Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Biological/Vaccine: LP-005

Participants were administered LP-005 as an IV infusion every 4 weeks.

DRUG

Biological/Vaccine: LP-005

Participants were administered LP-005 as an IV infusion every 4 weeks.

DRUG

Biological/Vaccine: LP-005

Participants were administered LP-005 as an IV infusion every 4 weeks.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

Sponsors

Lead Sponsor

Longbio Pharma
All Listed Sponsors
lead

Longbio Pharma

INDUSTRY